VSIG8-based chimeric proteins
By developing a monoclonal protein containing VSIG8 and OX40L exo-domain, the problems of low response rate and great side effects of existing immunotherapy to cancer patients are solved, and the purpose of enhancing immune response and improving anti-tumor effects is achieved.
JP2025065443AInactive Publication Date: 2025-04-17SHATTUCK LABS INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025020276
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-02-27
- Filing Date
- 2025-02-10
- Publication Date
- 2025-04-17
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Existing immunotherapy has low response rates to cancer patients and has serious side effects, limiting the window for treatment.
Method used
A monoclonal protein containing V set and immunoglobulin domain 8 (VSIG8) ex-domain, bound to an ex-domain in the oxidative region (OX40L), regulates the immune response through direct receptor/ligand interaction.
Benefits of technology
This monoclonal protein can simultaneously inhibit immunosuppressive signals and activate immune stimulation signals, reduce immunosuppressive cells, promote the transformation of the inflammatory environment, and improve anti-tumor effects.
✦ Generated by Eureka AI based on patent content.
Abstract
To provide novel methods and compositions that provide effective immunotherapies.SOLUTION: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and / or inflammatory diseases.SELECTED DRAWING: Figure 14A
Need to check novelty before this filing date? Find Prior Art